Table 16.
Efficacy of Technivie™ with or without ribavirin for 12 weeks.
| Cirrhosis | Prior treatment | SVR12 rate |
Study and trial phase | Ref. | ||
|---|---|---|---|---|---|---|
| GT-1 1b | GT-2 | GT-4 | ||||
| 12.5 mg ombitasvir + 75 mg paritaprevir + 50 mg ritonavir fixed-dose two pills QD for 12w | ||||||
| No cirrhosis | Experienced | 88.9% (16/18) | 72.2% (13/18) | Phase 2 | Chayama et al., 2015 | |
| Experienced | 90% (36/40) | PEARL-I, phase 2b | Lawitz et al., 2015c | |||
| Naïve | 95.2% (40/42) | 90.9% (40/44) | PEARL-I, phase 2b | Hezode et al., 2015 | ||
| Naïve | 95.7% (198/207) | GIFT-I, phase 3 | Kumada et al., 2015b | |||
| Experienced | 96.5% (110/114) | |||||
| Cirrhosis |
Naïve | 97.9% (46/47) | PEARL-I, phase 2b | Lawitz et al., 2015c | ||
| Experienced | 96.2% (50/52) | |||||
| Naïve | 100% (9/9) | GIFT-I, phase 3 |
Kumada et al., 2015b |
|||
| Experienced | 90.9% (30/33) | |||||
| 12.5 mg ombitasvir + 75 mg paritaprevir + 50 mg ritonavir fixed-dose two pills QD plus ribavirin BID for 12w | ||||||
| No cirrhosis | Naïve | 100% (42/42) | PEARL-I, phase 2b | Hezode et al., 2015 | ||
| Experienced | 100% (49/49) | |||||